MELVILLE, N.Y., June 17, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, today announced that its Board of Directors has authorized a stock repurchase program under which the Company may repurchase up to $2 million of its outstanding common stock through June 16, 2026.
Winner of the “Biotherapies and Bioproduction” call for projects under the France 2030 plan, EVerZom receives €3 million in government funding to industrialize its exosome bioproduction technology
DELRAY BEACH, Fla., June 10, 2025 /PRNewswire/ -- The global Exosome Research Market, valued at US$189.4 million in 2024 stood at US$214.4 million in 2025...